PMID- 27561266
OWN - NLM
STAT- MEDLINE
DCOM- 20170223
LR  - 20181113
IS  - 1432-1041 (Electronic)
IS  - 0031-6970 (Linking)
VI  - 72
IP  - 11
DP  - 2016 Nov
TI  - High prevalence of potential drug-drug interactions in patients with 
      castration-resistant prostate cancer treated with abiraterone acetate.
PG  - 1391-1399
AB  - PURPOSE: Abiraterone acetate (AA), used to treat metastatic castration-resistant 
      prostate cancer (mCRPC), inhibits androgen biosynthesis by blocking cytochrome 
      P450 (CYP) 17A1. It also inhibits other cytochromes involved in the metabolism of 
      various widely used medications. As such, there is presumably a high potential 
      for drug-drug interactions (DDIs) that can diminish the efficacy of AA or 
      concurrent medications, or increase the risk of DDI-related adverse events (AEs). 
      However, the scale of AA-associated DDIs is currently unknown. METHODS: We 
      conducted a retrospective review of pharmacy records and electronic patient 
      charts to retrieve individual drug histories and on-treatment AEs of mCRPC 
      patients beginning AA therapy in a tertiary care setting. Potential DDIs were 
      analyzed using two commercial databases, Lexicomp and Micromedex. RESULTS: 
      Eighty-four informative patients were identified. Sixty-five patients (77 %) and 
      44 patients (52 %) were flagged for one or more potential DDIs by the Lexicomp 
      and Micromedex databases, respectively. One hundred eighty-four potential DDIs 
      were identified overall, with a median of 1 DDI per patient in both databases. 
      Possibly due to rigorous DDI screening before AA treatment initiation, we did not 
      identify a definite instance of DDI-related AEs. CONCLUSIONS: The use of 
      commercial DDI databases suggests a substantial risk of potentially consequential 
      DDIs in mCRPC patients undergoing AA therapy. However, prospective investigations 
      with larger patient populations are required to better establish the clinical 
      relevance of these DDIs.
FAU - Jamani, Rehana
AU  - Jamani R
AD  - Sunnybrook Odette Cancer Centre, Sunnybrook Health Sciences Centre, 2075 Bayview 
      Avenue, Toronto, ON, M4N 3M5, Canada.
AD  - Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, 2075 Bayview 
      Avenue, Toronto, ON, M4N 3M5, Canada.
FAU - Lee, Esther K
AU  - Lee EK
AD  - Sunnybrook Odette Cancer Centre, Sunnybrook Health Sciences Centre, 2075 Bayview 
      Avenue, Toronto, ON, M4N 3M5, Canada.
AD  - Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, 2075 Bayview 
      Avenue, Toronto, ON, M4N 3M5, Canada.
FAU - Berry, Scott R
AU  - Berry SR
AD  - Sunnybrook Odette Cancer Centre, Sunnybrook Health Sciences Centre, 2075 Bayview 
      Avenue, Toronto, ON, M4N 3M5, Canada.
FAU - Saluja, Ronak
AU  - Saluja R
AD  - Sunnybrook Odette Cancer Centre, Sunnybrook Health Sciences Centre, 2075 Bayview 
      Avenue, Toronto, ON, M4N 3M5, Canada.
FAU - DeAngelis, Carlo
AU  - DeAngelis C
AD  - Sunnybrook Odette Cancer Centre, Sunnybrook Health Sciences Centre, 2075 Bayview 
      Avenue, Toronto, ON, M4N 3M5, Canada.
AD  - Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street, 
      Toronto, ON, M5S 3M2, Canada.
FAU - Giotis, Angie
AU  - Giotis A
AD  - Sunnybrook Odette Cancer Centre, Sunnybrook Health Sciences Centre, 2075 Bayview 
      Avenue, Toronto, ON, M4N 3M5, Canada.
FAU - Emmenegger, Urban
AU  - Emmenegger U
AD  - Sunnybrook Odette Cancer Centre, Sunnybrook Health Sciences Centre, 2075 Bayview 
      Avenue, Toronto, ON, M4N 3M5, Canada. urban.emmenegger@sunnybrook.ca.
AD  - Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, 2075 Bayview 
      Avenue, Toronto, ON, M4N 3M5, Canada. urban.emmenegger@sunnybrook.ca.
AD  - Institute of Medical Science, University of Toronto, 1 King's College Circle, 
      Toronto, ON, M5S 1A8, Canada. urban.emmenegger@sunnybrook.ca.
LA  - eng
PT  - Journal Article
DEP - 20160825
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
RN  - 0 (Antineoplastic Agents)
RN  - EM5OCB9YJ6 (Abiraterone Acetate)
SB  - IM
MH  - Abiraterone Acetate/*adverse effects/*therapeutic use
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/*adverse effects/*therapeutic use
MH  - Databases, Factual
MH  - Drug Interactions
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Polypharmacy
MH  - Prostatic Neoplasms, Castration-Resistant/*drug therapy
MH  - Retrospective Studies
OTO - NOTNLM
OT  - *Abiraterone acetate
OT  - *Castration-resistant prostate cancer
OT  - *Drug-drug interactions
EDAT- 2016/08/27 06:00
MHDA- 2017/02/24 06:00
CRDT- 2016/08/27 06:00
PHST- 2016/05/04 00:00 [received]
PHST- 2016/08/17 00:00 [accepted]
PHST- 2016/08/27 06:00 [pubmed]
PHST- 2017/02/24 06:00 [medline]
PHST- 2016/08/27 06:00 [entrez]
AID - 10.1007/s00228-016-2120-3 [pii]
AID - 10.1007/s00228-016-2120-3 [doi]
PST - ppublish
SO  - Eur J Clin Pharmacol. 2016 Nov;72(11):1391-1399. doi: 10.1007/s00228-016-2120-3. 
      Epub 2016 Aug 25.